NCT03258398 - A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

March 26, 2019

Study Completion Date

May 13, 2019

Conditions

Microsatellite Stable Relapsed or Refractory Colorectal Cancer

Interventions

DRUG

eFT508

eFT508 will be taken orally (PO) twice a day (bid).

DRUG

Avelumab

Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter

Trial Locations (7)

Florida Cancer Specialists, Sarasota

Tennessee Oncology, Nashville

Mayo Clinic, Rochester

Kansas City Research Institute, Kansas City

MD Anderson Cancer Center, Houston

Sarah Cannon Research Institute at HealthONE, Denver

Mayo Clinic, Scottsdale